ERBB2 and neoplasm: After pretreatment with blocking antibodies, the targeting F-SERS dots (the anti-HER2-FAF610-SERSRITC dots and anti-EGFR-FAF610-SERSFITC dots) were sprayed directly on the surface of the tumor tissue.